[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558380":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":25,"responsibleParty":39,"collaborators":25,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":25,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":25,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":25,"overallStatus":60,"whyStopped":25,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":25},{"fullName":5,"class":6},"Loma Linda University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Iron every other day","EXPERIMENTAL","Oral iron daily at 6 mg (elemental)\u002Fkg\u002Fday (max 200 mg elemental) taken every other day.",[13],"Drug: iron sulfate",{"label":15,"type":16,"description":17,"interventionNames":18},"Iron every day","ACTIVE_COMPARATOR","Oral iron daily at 6 mg (elemental)\u002Fkg\u002Fday (max 200 mg elemental) taken every day.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","iron sulfate","Oral iron administration",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Albert Kheradpour, MD","Loma Linda Univeristy","PRINCIPAL_INVESTIGATOR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":25,"email":35},"CONTACT","909.651.1910","akheradp@llu.edu",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":25},"Noela Ndrekaj, PharmD","909.651.1926",{"type":40,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100558380","phase-4-daily-iron-vs-every-other-day-iron-for-pediatric-patients-with-ida-100558380",false,"NCT06550362","Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA","A Randomized Controlled Trial Comparing Daily Oral Iron Administration to Every Alternate Day Iron Administration in the Treatment of Iron Deficiency Anemia in Pediatric Patients.","Inclusion Criteria:\n\n* Confirmed Iron Deficiency Anemia\n* Pediatric patients (1-18 years of age) without regard of gender, race, ethnicity nor language.\n* Able and willing to take oral iron (tablet or liquid).\n\nExclusion Criteria:\n\n* Pregnant or lactating patients\n* Known allergies or intolerance to oral iron formulations\n* Concomitant chronic medical conditions affecting iron metabolism\n* Short gut syndrome\n* Celiac disease\n* Inflammatory bowel disease\n* Cancer\n* Chronic kidney disease\n* Blood transfusions in the past 3 months\n* IV iron administration in the past 3 months\n* Oral iron supplementation in the past 2 weeks","ALL","1 Year","18 Years",{"count":52,"type":53},100,"ESTIMATED","INTERVENTIONAL",[56],"PHASE4","Iron Deficiency Anemia (IDA) is a prevalent global health issue affecting a significant proportion of the population, including children. While daily oral iron supplementation is a common approach to treat IDA, concerns regarding side effects and compliance have led to exploration of alternative dosing schedules, such as every-other-day. This study aims to investigate the efficacy and safety of daily versus every other day oral iron supplementation in the management of IDA in pediatric patients.",[59],"Iron Deficiency Anemia","NOT_YET_RECRUITING","2026-01-28",{"date":63,"type":64},"2026-01-30","ACTUAL",{"date":66,"type":53},"2026-05",{"date":68,"type":53},"2027-05",{"name":5,"class":6}]